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Abstract 
Topical formulations aim to target the skin for a variety of cosmetic, protective or 
therapeutic needs. Despite the use of creams and ointments over the millennia, the 
bioavailability of actives from topical preparations remains quite low, often not exceeding 1-
2% of the applied dose. In this review we examine the reasons underlying the poor 
performance of topical preparations. We also outline a rational approach, based on Fick’s 
laws of diffusion, to develop advanced topical formulations. Methodologies which are 
currently used in research and development are critically examined and the importance of 
understanding the fate of the vehicle as well as the active is emphasised. Advanced topical 
formulation development will also be facilitated by emerging and sophisticated analytical 
techniques that are able to probe real time delivery of actives to the skin. A good 
understanding of the underlying physical chemistry of both the formulation and the skin is 
crucial in the development of optimised topical products. 
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Forenote 
This is to acknowledge the contribution that Sandy Florence has made to the 
pharmaceutical sciences, in particular, the role of physical chemistry in developing 
optimised formulations. 
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1. Introduction - The Watershed 
In the same way that our calendar runs from BC to AD, there was a marked 
watershed in our understanding of topical drug deliver before steroids (BS) and after 
steroids (AS).  The major steroid in question was hydrocortisone which was developed some 
60 years ago (Fourman et al., 1950).  Delivery of agents to the skin has been documented by 
the Egyptians (BC), the Romans (AD) and in mediaeval times when ‘flying ointment’ was 
recorded (Hadgraft and Lane, 2016). It is interesting to note that, in the 13th – 14th centuries 
that it was known how to extract hallucinogenic materials from plants (e.g. mandrake).  The 
extract had to be treated with lime to render the active more permeable through the skin 
(Burton, 1972). We now know that the base form was liberated and it was then 
compounded into a fat (i.e. a simple formulation was manufactured). Even though flying 
ointment was known and it was recognised that nitroglycerin induced headaches in 
armament workers by the late 1800s and also that nicotine could cause death as a result of 
skin penetration, the skin was largely regarded as an impermeable barrier (Laws, 1910; 
Faulkner, 1933; Rothman, 1943). Before steroids, very little was known about the role of the 
formulation and how delivery through the skin could be markedly affected by simple 
changes to the formulation. 
 
2. Skin structure and route of penetration 
For decades it has been appreciated that the stratum corneum, the outer layer of 
the skin is the rate controlling membrane to permeation. It is a unique barrier that is only 
some 15 micrometres thick (Hadgraft and Lane, 2011). It has evolved to prevent excessive 
water loss from mammals. How does it achieve this? It is comprised of dead keratinised cells 
that overlap, embedded in a lipid matrix, and the structure has been regarded as resembling 
a brick wall (Michaels et al., 1975). This is interspersed by hair follicles and sweat glands 
(Figure 1). There has been much debate concerning the route of penetration. Scheuplein 
and co-workers published a series of papers in the mid sixties to mid seventies which 
covered various aspects of percutaneous penetration. This included mechanisms and routes 
of penetration (Scheuplein 1965,1966,1967), the effect of temperature (Blank et al., 1967) 
and specific details on steroid permeation (Scheuplein et al., 1969). They also considered 
effects of surfactants (Scheuplein and Ross, 1970) and penetration from solvent deposited 
solids (Scheuplein and Ross, 1974).  
6 
 
Over the years, a number of biophysical techniques have been used to identify the 
major route. Experiments by Albery and Hadgraft (1979) using methyl nicotinate as the 
probe indicated that the primary route was intercellular, i.e. around the corneocytes. This 
was substantiated by a thermodynamic analysis on the penetration of water (Potts and 
Francoeur, 1990) and by the imaging of butanol (Nemanic and Elias, 1980), mercuric 
chloride (Bodde et al., 1989), norethindrone, oestradiol (Neelissen et al., 2000) and a 
lipophilic fluorescent dye Nile Red (Talreja et al., 2001). When the first studies were 
conducted to determine the route, little was known about the constituents of the 
intercellular spaces. However advanced analytical and scattering techniques have shown 
that there is a complex array of lipids (predominantly ceramides) that are structured into 
ordered bilayers (Garson et al., 1990; Bouwstra et al., 1991). Thus a diffusing permeant, 
whether it be water or a xenobiotic, encounters a tortuous path and has to cross, 
sequentially, hydrophilic and hydrophobic domains. The lipid chains of the ceramides close 
to the polar head groups are held tightly together which further slows progress of the 
permeant as it has to diffuse through a viscous region.  The length of the tortuous path will 
be a function of the number of cell layers and their size; this is a simple geometric fact that 
has been investigated using trans epidermal water loss (TEWL) studies in humans (Hadgraft 
and Lane, 2009; Machado et al., 2010). TEWL varies from site to site on the body and is 
largest on areas such as the face where there are fewer layers of cells and the cell size is 
smaller. Both factors impact on skin permeability and the facial region is particularly 
permeable hence the caution advised when using steroids on the face (Eichenfield et al., 
2014).  It is also interesting to note that the penetration of methyl nicotinate varies from 
site to site along the back (Fountain et al. 1969b). 
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Figure 1. Potential pathways through the stratum corneum. 1 - Transappendageal route 
through (A) hair follicles and (B) sweat glands; 2 - Transepidermal route across intact SC via 
(A) intercellular lipids and (B) via keratinised cells (or transcellular). 
 
One of the other implications of the intercellular route is the fact that when a 
formulation is spread over the skin surface only a small ‘active’ area for diffusion is 
available. The bulk of the area, the large surface of the corneocytes will not be accessible for 
a permeant.  This is probably the major contributing factor to the low bioavailability (~1-3%) 
of steroids when applied to the skin as solution in acetone (Feldmann and Maibach, 1965; 
1966; 1969). It is probable that the steroids crystallise on and in the upper intercellular 
channels of the skin and are therefore unavailable for continued diffusion; we have recently 
presented evidence for this phenomenon (Hadgraft and Lane, 2016). This would also explain 
the steroid reservoir mentioned above.  It has been demonstrated that this is particularly 
pronounced when DMSO was used as a solvent. DMSO is a particularly good solvent and an 
excellent penetrant. It is does not stay on the skin or in the skin and when used as a vehicle 
for a steroid the active will crystallise essentially leaving it stranded and unable to dissolve. 
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It will then be sloughed off the skin, which is a particularly dynamic membrane, the stratum 
corneum having an average turnover time of 14 days. 
 
3. Corticosteroids and nicotinic acid esters 
Corticosteroids penetrate through the stratum corneum and constrict the blood 
vessels at the epidermal – dermal junction.  This manifests itself as a pallor, the degree of 
which could be related to the potency of the steroid and the amount permeated (McKenzie 
and Stoughton, 1962). On the other hand, the nicotinates cause vasodilatation of the blood 
vessels and the onset of erythema could be related to the degree of penetration (Fountain 
et al., 1969a). The advent of the more potent corticosteroids led to more investigations on 
formulation effects. It was soon recognised that hydration of the skin, using occlusion, 
improved the permeation of the steroids and that the degree of penetration was related to 
the concentration applied (McKenzie and Stoughton, 1962). At the same time Cronin and 
Stoughton (1962) used ethyl nicotinate to show that there was regional variation in skin 
permeability. Barrett et al. (1964) used methyl nicotinate in various formulations to show 
that there were considerable differences in absorption when equal concentrations of the 
nicotinate were dissolved in aqueous cream, oily cream, white soft paraffin or macrogol 
ointment (Table 1). These authors also showed permeation was directly related to 
concentration.  
 
Table 1: Penetration of methyl nicotinate from various topical vehicles. Adapted from 
Barrett et al. (1964) 
Concentration  
of methyl  
nicotinate 
Time of onset of erythema (min) 
 
Aqueous Cream  Oily Cream  White soft paraffin  Macrogol 
1 3.3 4.1 5.3 8.7 
0.5 4.0 4.5 6.6 10.8 
0.25 - - - 17.1 
0.1 4.6 5.2 8.0 22/3 
0.05 5.9 6.8 13.1 Not measured 
0.01 7.4 10.5 19.7 Not measured 
0.005 10.9 12.5 Not measured Not measured 
0.001 Not measured Not measured Not measured Not measured 
 
In the mid-60s there was an interest in enhancing skin penetration and one of the 
most researched solvents was dimethyl sulphoxide (DMSO). Stoughton (1965) showed that 
the penetration of fluocinolone acetonide was enhanced by DMSO and that a steroid 
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reservoir was induced.  However, the reason for the formation of the reservoir was unclear.  
Other agents were also examined as potential penetration enhancers such as dimethyl 
formamide and dimethyl acetamide (Feldmann and Maibach, 1966). These vehicles also 
influenced transepidermal water loss (TEWL) as reported by Baker (1968). Sarkany et al. 
(1965) investigated formulation effects and conducted a clinical study on eczema and 
psoriasis treatment. Unequivocal evidence showing a link between vasoconstrictor effect 
and clinical efficacy could not be demonstrated. 
 
4. Physicochemical determinants of topical delivery 
When steroid treatment was coming to the fore in the late 50s, Higuchi (1960) 
presented a paper showing the importance of Fick’s laws of diffusion in understanding 
percutaneous absorption (Equation 1). 
 
     
  
  
 E  Equation 1 
 
Most simply this analysis shows the significance of the driving force for diffusion, D 
across a membrane of thickness, h. At its most basic this is the concentration, c, of the 
active but strictly it is the chemical potential, which is related to the concentration and the 
activity coefficient. If an active is applied in a solvent (and the solvent does not interact with 
the skin) the flux of the active across the skin will be related to the degree of saturation. It is 
therefore possible to apply formulations which contain different concentrations of the drug 
and their penetration rates will be the same. This was shown by Hadgraft et al. (1973) in 
which methyl nicotinate, at different concentrations but at the same chemical potential was 
applied in simple water – glycerol mixtures. (Figure 2) The time of onset of erythema was 
the same thus demonstrating the importance of chemical potential. Similar results were 
found for the steroids (Lippold and Schneeman, 1984). These workers showed that the 
degree of blanching induced by a steroid was dose dependent up to the point at which the 
steroid was at its saturated solubility in the formulation.  Concentrations above the 
solubility limit (i.e. suspensions) did not improve the vasoconstriction response; in simple 
terms a 1% suspension will be as effective as a 5%. 
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Figure 2. Appearance of erythema following application of filter paper impregnated with a 
solution of methyl nicotinate to the forearm 
 
The fact that the chemical potential is important also means that if it can be 
‘artificially’ raised above the solubility limit, there is an opportunity to improve delivery.  
Supersaturated states are thermodynamically unstable but if they can be transiently 
stabilised over the application time of the formulation, enhanced permeation is possible.  
Interestingly this hypothesis was first tested and proved using steroids (Coldman et al., 
1969).  They used the presence of a volatile solvent, which evaporated on application to the 
skin, to create a supersaturated state in the non-volatile solvent. After evaporation the 
active is delivered into the skin from the so-called residual phase. Supersaturation was 
taken further in a series of publications by Davis and co-workers (Davis and Hadgraft, 1991; 
Pellett et al., 1994; Pellett et al., 1997a) who used a mixing process to create 
supersaturation (Figure 3), which was stabilised using anti-nucleant polymers such as 
hydroxypropylmethyl cellulose (HPMC).  
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Figure 3. The black line represents the saturated solubility of a drug in the binary mixture of 
solvent “a” and solvent “b”. By mixing a saturated solution in “system b” with pure “system 
a” supersaturated ( ) solutions can be obtained. Adapted from Davis et al. (1991). 
 
Initial studies with hydrocortisone were conducted on model membranes and skin 
but the work culminated in an in vivo skin blanching study on hydrocortisone acetate. By 
using supersaturation it was possible to make formulations that were bioequivalent with the 
commercially available 1% preparation (Davis and Hadgraft, 1993). These supersaturated 
preparations contained 0.02% of the active, underlining the potential of the approach for 
development of more efficacious and cost-effective topical formulations. For piroxicam, the 
amount of the active which penetrated human skin in vitro increased linearly with 
increasing degree of saturation (Pellet et al., 1997b). Moreover, an excellent correlation 
(r2=0.97) was also obtained between amounts of active extracted from the stratum 
corneum and degree of saturation (Figure 4).  
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Figure 4 (a) Cumulative amounts of piroxicam diffused across human skin following 
application in saturated and supersaturated solutions and (b) Corresponding amounts of 
piroxicam in the stratum corneum as determined by tape stripping at the end of the 
permeation experiments (Adapted from Pellet et al., 1997b).  
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Another way of considering chemical potential effects is to look at Fick’s first law of 
diffusion in terms of concentration and partition coefficient (Equation 2). 
 
     
     
 
 Equation 2  
 
Again if it is assumed that the vehicle does not interact with the skin, the 
concentration just inside the skin, at the interface of the skin and the vehicle, will be 
Kc,where K is the skin – vehicle partition coefficient and c the concentration of the active in 
the vehicle.  In an interesting series of papers using fluocinolone acetonide and its acetate 
ester, Ostrenga et al (1971a,b) found that an optimum vehicle could be identified where the 
product of K and the solubility was at a maximum. This was demonstrated using a series of 
propylene glycol water mixtures and for the acetonide, the optimum concentration was 
about 30% PG / 70% water whereas for the acetate ester it was the reverse i.e. 70% PG 
/30% water (Figure 5). This is in line with the fact that the acetate ester is the more 
lipophilic of the two molecules.  
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Figure 5. Blanching response following topical application of fluocinolone acetonide 
(blue circles) and fluocinolone acetonide acetate (green circles) in various PG:water 
mixtures (Adapted from Ostrenga et al., 1971a).  
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A further factor in Higuchi’s paper (1960), in which the role of Fick’s laws of diffusion 
is discussed, is the diffusion coefficient, D. In general terms the smaller the active, and thus 
the lower the molecular weight, the faster the active will diffuse through the skin. This 
means that the three major determinants in controlling skin penetration are (i) solubility of 
the active (ii) partition behaviour and (iii) diffusion coefficient.  In general, those compounds 
that permeate well have a log octanol – water partition coefficient (Log Po/w) of about 2, 
good solubility in both oils and water, and are relatively small. These are the characteristics 
of two of the drugs that are currently delivered via the transdermal route, nitroglycerin and 
nicotine. All of the above statements have the caveat that the formulation components do 
not interact with the skin, clearly some will and the implications of this can be profound.  
Before discussing the interplay between excipients and the skin, it is important to identify 
the rate controlling process in dermal penetration and how this is influenced by the 
structure of the skin and the route of penetration. 
 
5. Penetration enhancers 
Since the barrier properties of the stratum corneum are formidable, it has been a 
challenge to produce medicines which effectively treat skin disorders.  Many actives do not 
have ideal physicochemical properties and therefore the formulation scientist has significant 
difficulties in optimising their delivery. These constraints led to extensive research into 
compounds that enhance penetration. The first major compound was DMSO but this was 
soon followed by many more. With the application of various biophysical techniques it 
proved possible to describe some of the possible mechanisms of action.  Considering Fick’s 
first law of diffusion the two factors that can be modified are the partition behaviour and 
the diffusion coefficient (Hadgraft, 2009; Lane, 2013). If a formulation component enters 
the structured lipids of the stratum corneum it may alter their solubility characteristics and 
will thereby alter the partition from the formulation into the skin.  If this is favourable, 
enhanced permeation will result. Alternatively, the excipient may intercalate into the 
structured lipids and alter their fluidity.  If it makes them more fluid diffusion through them 
will be more rapid and, again, enhanced permeation could result. 
It is very difficult to deconvolve the two effects of partition and diffusion on 
membrane penetration of an active. However, using deuterated materials and Attenuated 
Total Reflectance - Fourier Transform Infra Red (ATR-FTIR) spectroscopy it has been possible 
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to show that oleic acid forms pools in the structured lipids and that penetration of an active 
is enhanced as a result of diffusion through these more fluid domains (Potts et al., 1991).  
On the other hand, Azone also fluidises the structured lipids but intercalates into them in a 
more homogenous way (Harrison et al., 1996b).  The major structural difference is the cis 
double bond in oleic acid which is probably responsible for the pool formation.  Considering 
the molecular structure of Azone, the seven membered ring interacts with the polar 
headgroups of the skin lipids.  This forces the alkyl chains apart and they therefore become 
more fluid. 
It has been suggested that small solvent molecules such as propylene glycol or 
diethyleneglycol monoethylether (Transcutol), improve the solubility of penetrants in the 
stratum corneum (Kasting et al., 1993; Watkinson et al., 2009; Osborne, 2011). This effect 
has also been studied using ATR-FTIR (Harrison et al., 1996a).  The fact that both D and K can 
be influenced means that if excipients in a formulation can favourably alter both, then 
synergistic effects are found.  This had previously been reported for mixtures of Azone and 
propylene glycol (Wotton et al., 1985). Supersaturation was described above and it is also 
possible to obtain synergistic effects when supersaturation is combined with chemical 
penetration enhancement (Davis et al., 2002). 
 
6. Solvent effects 
With the advent of in vivo confocal Raman spectroscopy it has been possible to 
examine the effects of excipients on the distribution of actives within the stratum corneum.  
Mohammed et al. (2014) examined the penetration of nicotinamide from different 
excipients, both singly, and in combinations (binary and ternary). One of the important 
findings of the work was to show that the amount of active in the stratum corneum was 
related to the uptake of the solvent in the stratum corneum (Figure 6). Very few studies 
have been conducted on the uptake of emollients or their penetration across the skin.  
Small molecules such as ethanol and propylene glycol have been examined and they 
permeate quite quickly (Berner et al., 1989; Liu et al., 1991; Trottet et al., 2004).  Larger, 
more lipophilic emollients such as isopropyl myristate and isostearyl isostearate have not 
been researched in any detail. Unpublished work from our laboratory has shown that the 
uptake is small, and because of the high log P values of these materials they will not 
permeate across the skin (Oliveira, 2009).  They will have a high residence time in the skin.  
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Santos et al. (2010) studied the permeation of oxybutynin from finite doses in either 
propylene glycol or octyl salicylate.  They found that the propylene glycol permeated rapidly 
and suggested that the active was left crystallised on and in the skin because of the 
disappearance of the solvent. This contrasted with the formulations that contained octyl 
salicylate where delivery of oxybutynin was better and more sustained. Because the octyl 
salicylate had a longer residence time in the skin, it maintained the active in solution and 
therefore available for delivery to the deeper layers. 
 
 
Figure 6: Correlation between signal intensity of niacinamide and signal intensities of PG or 
DMI which permeated into the SC in vivo with depth (0, 4, 8, 12, 16, 20 into the SC) for the 
mid ventral forearm (n=8; Mean ± S.D.). Adapted from Mohammed et al. (2014). 
 
7. Finite versus infinite doses in skin permeation studies  
One of the important points in the studies conducted by Santos et al. (2010) was the 
use of finite doses.  In the clinic, a typical dose to the skin is 2 mg/cm2.  Many studies, in 
vitro, use infinite doses and often this does not give a true representation of how the 
excipients will work in vivo.  For example, a representative clinical dose of propylene glycol 
will be subject to both evaporation, from the skin surface, and diffusion through the skin.  
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depletion and the effects of PG in the skin may be significantly overestimated (Hadgraft and 
Lane, 2016). . 
There are not only problems associated with the use of finite doses, it should also be 
noted that many experiments have been conducted on rodent skin, which also gives 
misleading results.  For a true representation of topical delivery to man, human skin should 
be used with as close a clinical dose as possible.  The closest one can get to this, in the 
absence of human tissue, is pig tissue. A number of studies have reported the similarity 
between pig and human skin tissue with reference to barrier properties (Dick and Scott, 
1992; Singh et al., 2002; Barbero and Frasch, 2009; Luo et al., 2016). 
 
8. Psychorheology 
The cosmetics industry would not exist if it did not produce products that were 
acceptable to consumers.  It is extremely good at producing products that ‘feel good’ and 
the public want to buy again and again.  The pharmaceutical industry could learn from this 
and perhaps patient compliance would be better if topical products were more cosmetically 
acceptable. The subject has not been studied extensively but was recognised by Boyd 
(1976).  It is clear that medicines for treating mild eczema have to have much better ‘feel’ 
than, for example, a product to treat melanoma.  However, in modern product design there 
should be an element which considers the desirability of using the product on a regular and 
repeated basis.  There are many publications, in the pharmaceutical literature, which 
consider the basic rheological properties of the product, but one should question their 
relevance in relation to their ability to deliver the active and how the patient perceives 
them.  
 
9. Conclusions - Advanced Topical Formulations 
Important principles underlying the basis for the design of advanced topical 
formulations have been known for a number of years but all the elements are rarely 
considered in an holistic approach. Firstly, the properties of the active should be taken into 
account.  Ideally it will have a log Po/w around 2, and will have reasonable solubility in both 
oils and water, usually associated with a low melting point.  If there are several candidates 
that are structurally related then there will be a balance between the ideal physicochemical 
properties and the potency. 
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The active needs to be delivered to the ‘active’ regions of the skin, i.e. the 
intercellular spaces at as high a thermodynamic activity as possible.  This means that it will 
be close to saturation and therefore subject to the possibility of crystallisation.  There needs 
to be the possibility of lateral diffusion to the intercellular spaces from the formulation 
deposited onto the corneocytes. It is possible that the enhanced penetration from some 
liposomal formulations is a result of the formation of a lipid layer on the skin surface 
through which lateral diffusion is facilitated.  Rapid evaporation of a volatile solvent is likely 
to result in supersaturation but this will need to be stabilised with the judicious choice of 
anti-nucleant polymers.   
It is important to recognise the evaporation of formulation components, such as 
water, and the residual phase that remains is of most importance in the formulation design.  
The residual phase should present the active at a high activity state but also deliver 
appropriate enhancers into the skin, most particularly solvents that will remain in the 
stratum corneum and maintain the active in solution.  The solubility characteristics of the 
residual phase both in terms of the active and the skin lipids need to be considered.  In 
order that the emollients also penetrate into the SC, it is important that they are also at a 
high thermodynamic activity.  
These simple rules may be difficult to achieve, in reality, but will result in more 
effective topical delivery. Other factors that will also be built in to the final formulation are 
clearly the feel of the product, as discussed above, and also its stability. The increased 
sophistication of biophysical techniques, particularly those that can be used in vivo, will aid 
the formulation process and give much more insight into the future developments of topical 
formulation design. 
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